Overview
ABEO market data
Price History
ABEO price chart · 1M
- O
- 5.90
- H
- 5.97
- L
- 5.86
- C
- 5.94
- Vol
- 53,947.00
- Source
- US equities market feed
- Observed
- Sep 3, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $5.90
- Previous Close
- $5.97
- Day High
- $5.97
- Day Low
- $5.86
- 52 Week High
- $7.62
- 52 Week Low
- $5.08
- 7 Day Return
- -1.90%
- 30 Day Return
- -12.98%
- 90 Day Return
- +8.70%
- 1 Year Return
- +2.68%
- Daily Notional Volume
- $320.2K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 5.50 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.08 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.46 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 490.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.00 – $7.65 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $363.9M · P/B 1.79 · P/S 25.03.
Company News
8 captured
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21Benzinga · Aug 14, 2026, 5:00 PM
Abeona Therapeutics Q2 2026 Earnings Call TranscriptBenzinga · Aug 13, 2026, 3:07 PM
Abeona Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.Benzinga · Aug 13, 2026, 11:59 AM
Abeona Therapeutics Q2 EPS $(0.35) Misses $(0.23) Estimate, Sales $11.380M Miss $12.239M EstimateBenzinga · Aug 13, 2026, 11:31 AM
8-K filing — ABEONA THERAPEUTICS INC. (ABEO)SEC EDGAR · Aug 13, 2026, 11:30 AM
Abeona Therapeutics Says CMS Granted New Technology Add-On Payment Status For ZEVASKYN Under Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final RuleBenzinga · Aug 4, 2026, 11:37 AM
Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis BullosaBenzinga · Jul 21, 2026, 11:37 AM
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Globenewswire Inc · Jul 1, 2026, 12:15 PM